BridgeBio Oncology Therapeutics (BBOT) Income towards Parent Company (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Income towards Parent Company for 3 years, with the latest figure at -$62.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 193.59% year-over-year to -$62.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$232.3 million (down 130.54% YoY) and the FY2025 annual result came in at -$233.0 million, down 98.14% from the prior year.
• Income towards Parent Company grew to -$62.1 million in Q1 2026 per BBOT's latest filing, from -$86.2 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $2.3 million in Q2 2024 and troughed at -$86.2 million in Q4 2025.
• A 3-year average of -$36.9 million and a median of -$21.1 million in 2025 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 32.97% in 2025, down 1955.37% in 2025.
• Over 3 years, Income towards Parent Company stood at -$64.8 million in 2024, then plunged by 32.97% to -$86.2 million in 2025, then grew by 27.96% to -$62.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$62.1 million, -$86.2 million, and -$85.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.